

How We've Had Your Back and Amplified the Biotech Industry's Voice

MASSBIO

The U.S. is still the best place to build a biotech. We're fighting to keep it that way.

FDA & Regulatory

Surveyed members on first-in-human (FIH) trials: 70% have already been hesitant to run trials in the U.S. — and 54% say recent FDA changes make them less likely to pursue U.S. FIH work

We're bringing the data directly to FDA and Capitol Hill

China & Global Competition

U.S. assets are being passed over on cost, and especially speed, not science; **MassBio's external innovation survey documents the shift in real-time**

The U.S. is still preferred on a level playing field — but that playing field is tilting

Drug Pricing

MassBio formally opposed Most Favored Nation pricing, **including both the GLOBE and GUARD proposals**

| Surveyed members reported hesitancy running clinical trials in U.S.

Early-stage biotech can't survive on venture alone. We know that, and we act like it.

SBIR/STTR

MassBio's active engagement with Senate negotiators helped deliver a 5-year reauthorization signed into law through 2031

The state pulls in more than 150 grants per year on average — this win lands directly in your companies

NIH

MassBio advocated loudly and consistently for NIH funding and Congress passed a budget that includes a \$400 million increase; Massachusetts receives 9.3% of all NIH funding nationally

Drive Life Sciences

Drive, MassBio's national accelerator, is already delivering results for scientific founders who haven't yet reached venture scale — and we're building what comes next: **a non-dilutive capital mechanism and an operational support platform** designed to move companies across the Valley of Death

| **Massachusetts ranks #2 nationally for SBIR/STTR awards — and MassBio helped make sure the program survived.**

Building a great biotech company in Massachusetts is harder than it should be. We're fixing that.

State Investment

Working closely with the MLSC on program design and capital allocation

MassBio's industry advocacy was a key factor in the design of BioBoost, MLSC's new biomanufacturing scale-up program

Real Estate & Housing

Lab and office leasing terms still favor landlords — **MassBio carries CEO feedback on lease flexibility to the state**

A member of One Commonwealth, we actively engage on housing affordability as a workforce retention issue

Leadership Pipeline

Termeer Ascend: Leadership in Practice, with the Termeer Institute, directly responds to what CEOs told us: **the leadership pipeline isn't keeping pace with the science**; the inaugural cohort is in process

Peer Roundtables

Peer roundtables for General Counsel, Human Resources, Patient Advocacy, and Facilities & Lab Operations — gathering counterparts to share best practices and work through common challenges

Lab and office leasing terms still favor lessors. MassBio is carrying that message directly to the state — your lease terms are a competitiveness issue.

If you're not in the room, you're not in the conversation. We make sure you're there.

Federal & State Access

MassBio brought 10 biotech CEOs to the State House for the Massachusetts Life Science Caucus — telling the story of early-stage biotech to legislators, Caucus co-chairs, and in private meetings with Healthcare Finance Chairman John Lawn & Senator Sal DiDomenico

Convened a CEO roundtable with **Senator Elizabeth Warren**, briefing her on the challenges facing MA biotechs — stayed in active dialogue with **Senators Ed Markey and Joni Ernst's** offices through SBIR reauthorization

Regulatory Relief

Connected the SEC with biotech CEOs voicing the challenges of going public as a small company — the SEC has since proposed amendments to permit semiannual reporting, a meaningful reduction in burden for public biotechs

Community & Visibility

State of Possible Conference put biotech CEOs center stage with candid conversations about risks, failures, and perseverance

CEO & Founder Link gives biotech leaders a peer community for networking, education, and collaboration

BiotechTV's CEO Conversations series puts local biotech CEOs on camera, in their own words, for an industry audience

76% of MassBio's 1,700+ members are companies of fewer than 50 people. That's who we show up for.